Carocell Bio

[Not Yet Scheduled]
Carocell Bio are developing novel anti-inflammatory peptides with nano-particle delivery to more safely treat serious inflammatory diseases. Our lead peptide is to prevent the formation of a scar after an operation – a $37B market.
We have achieved an Innovate UK grant and Seed funding to see if we can switch off the inflammation seen after a burn.
We are seeking investment of $10M, over the next two years, to take our lead to clinic ready.
$3.5M in 2022 will develop the formulation, conduct a mini-pig scar prevention study and engage with the regulators.
Our current investors have agreed to collaborate this next round.
I would like to tell you more about our exciting company and hope that we can meet.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
North Carolina
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
JEL3108
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5
Speaker
photo
CEO & Founder
Carocell Bio